Mike Owen | Oxford | Cambridge

Mike Owen has worked in biomedical research, and in the pharmaceutical and biotechnology industries for nearly 40 years. He currently serves as a director on seven boards.

He is the Chairman of Ossianix Inc, a privately held biotechnology company. He is also on the boards of Zealand Pharma A/S, Avacta Group plc, ReNeuron plc, Sareum plc, GammaDelta Therapeutics and Iksuda Therapeutics. Dr Owen is also an observer on the CRT Pioneer Fund Investment and Divestment committee , advises Abingworth LLP, and is Chairman of ReNeuron’s and Avacta’s SABs in addition to being on Orbit Biomedical’s SAB.

Prior establishing his Board portfolio, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company. Prior to co-founding Kymab, Dr Owen worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D.

Dr Owen received a BA degree from Oxford University in 1973 and a PhD from Cambridge University in 1976. He was elected a member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.
Close Menu